AU4969499A - Companion animal therapeutic treat - Google Patents

Companion animal therapeutic treat Download PDF

Info

Publication number
AU4969499A
AU4969499A AU49694/99A AU4969499A AU4969499A AU 4969499 A AU4969499 A AU 4969499A AU 49694/99 A AU49694/99 A AU 49694/99A AU 4969499 A AU4969499 A AU 4969499A AU 4969499 A AU4969499 A AU 4969499A
Authority
AU
Australia
Prior art keywords
sea cucumber
fractions
jerky
glucosamine
green tea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU49694/99A
Other versions
AU770392C (en
AU770392B2 (en
Inventor
Peter Donald Collin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coastside Bio Resources
Original Assignee
Coastside Bio Resources
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coastside Bio Resources filed Critical Coastside Bio Resources
Publication of AU770392C publication Critical patent/AU770392C/en
Publication of AU4969499A publication Critical patent/AU4969499A/en
Application granted granted Critical
Publication of AU770392B2 publication Critical patent/AU770392B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/616Echinodermata, e.g. starfish, sea cucumbers or sea urchins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Description

WO 00/01399 PCT/US99/15168 COMPANION ANIMAL THERAPEUTIC TREAT Field of the Invention The present invention involves the use of sea cucumber tissue fractions, in combination with kelp, 5 and/or green tea extracts, for the inhibition of inflammation. These therapeutic fractions are incorporated with ingredients which provide palatability into a delivery system as a user convenient and pet acceptable "jerky stick" or similar 10 animal "treat" format. Background of the Invention Dogs and other companion animals suffering from various forms of arthritis are in need of supplements which deliver active forms of anti-inflammatory agents 15 in a palatable manner. Glucosamine sulfate and glucosamine HCL and related products are described in various patents such as those by Henderson, et al, which teach the incorporation of glucosamines with other sulfated 20 polysaccharides, vitamin C and manganese in products aimed at cartilage health. It is believed that glucosamine, or similar products, provide one or more of the biochemical components which make up the matrix of mammalian cartilage. Glucosamine is a WO 00/01399 PCT/US99/15168 2 chondroprotective agent which acts as a competitive inhibitor of inflammatory agents produced by the body which attack the cartilage and/or joint fluid in the joints. 5 Green tea extracts have been shown to be potent inhibitors of inflammation and collagen-induced arthritis in mice. See, Haqqi, et al., Proc. Natl. Acad. Sci., USA, 96:4524-29 (1999). The polyphenolic subfraction of green tea, known as epigallocatechin-3 10 gallate (EGCg), has proven to be an inhibitor of cartilage degradation in mammals. Id. In an experiment, purified EGCg, from Sigma Chemical Supply, St. Louis, MO, was placed with bovine nasal cartilage explants at a concentration of 22pM. This mixture was 15 cultured for 5 days in the presence or absence of the pro-inflammatory cytokine, recombinant human tumor necrosis factor alpha at 3nM. The inhibition of both the basal and stimulated protcoglycan degradation by EGCg was measured using a colorimetric assay for 20 sulfated glycosaminoglycans. See, Farndale, et al., Biochem. Biophys. Acta, 4:883 (1986). The results showed that EGCg was a potent inhibitor of cartilage breakdown at the sub-cellular level. Jerky sticks, as are known in the dog treat 25 industry, are often combinations of meat or fish by products, gelatin, grains, vitamins, minerals, animal fat, preservatives such as BHT and BHA or mixed tocopherols that are mixed and extruded into various shapes, weights, and sizes which can vary widely. See, 30 U.S. patent No. 5,773,076 for a general description of the art. Jerky sticks are given to pets as rewards or for added nutrition, or both.
WO 00/01399 PCT/US99/15168 3 Both extracts from the sea cucumber and from green tea are known to have beneficial therapeutic effects in mammals. These beneficial effects could not be utilized by veterinarians and others skilled in the art 5 of animal care because they were not available in a palatable form. It is known to those skilled in the art of veterinary science that dogs and other mammals prefer palatability factors such as, fish, meat or meat by-products to enhance the attractiveness of 10 therapeutic products and increase patient compliance. Given the lack of a mode of delivery for these types of anti-inflammatory extracts that is both easy to administer for the caretaker and agreeable to the animal, there is a recognized need for the combination 15 of an acceptable delivery form and the therapeutic extracts. Summary of the Invention The present invention relates to a mode of delivery for biologically active fractions of sea 20 cucumber and green tea. In this regard, the present invention describes a "jerky stick" or "dog bone" as is known in the art, being combined with the palatability factors of meat and meat by-products, garlic, smoke flavor or cheese, and the additional co-factors of 25 glucosamine sulfate, glucosamine hydrochloride and/or green tea extracts or derivatives thereof for therapeutic treatment of inflammation and arthritis. Detailed Description of the Invention The present invention addresses the problem of 30 administration of anti-inflammatory treatments, WO 00/01399 PCT/US99/15168 4 specifically; sea cucumber products, glucosamines, kelps and green tea extracts by incorporating them into jerky treats with co-factors addressing the need to make the total product palatable to the animal in need. 5 The sea cucumber fraction delivery system for animals of the present invention includes the combination of glucosamines and/or kelp, and/or green tea extracts in the form, of a jerky stick, or "treat", as is popular in the dog-treat industry. 10 The "jerky stick" of the present invention combines certain ingredients and is made palatable by certain co-factors such as meats or flavorings known to those skilled in the art and include glucosamines or glucosamine derivatives. Sea cucumber body wall finely 15 divided, including the epithelial layer, muscle layer and collagen layer as an ingredient in a formed dog jerky stick is also an aspect of the present invention. These total sea cucumber skin fractions are also incorporated with glucosamines described above and 20 formed in various percentages of incorporation into jerky sticks with palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds. A suitable range of glucosamine concentration is between 1% and 50% of the final 25 product (by weight). These jerky sticks or manufactured "treats" are administered to dogs, cats and other animals and provide increased attractiveness to those animals in need of the therapeutic ingredients. 30 As used herein, the term "B1000" refers to the isolated epithelial layer of the sea cucumber, WO 00/01399 PCT/US99/15168 5 substantially free of the flower portion, muscle, collagenous tissues and viscera; the term "T2000" refers to the isolated flower portion of the sea cucumber, substantially free of 5 other portions of the sea cucumber body; the term "derivative" refers to any compound, fraction or combination thereof, derived from a sea cucumber or green tea fraction that has biological activity or nutritional properties; 10 the term "inflammation disorder" refers to any condition or disease in a warm-blooded animal having inflammation as a symptom or proximate cause. In one embodiment of the invention the delivery form "jerky treat" material contains the sea cucumber 15 fractions as disclosed in U.S. patent No. 5,770,205. Active anti-inflammatory compositions can be obtained from sea cucumber in a variety of ways. For example, sea cucumbers can first be cleaned of muscle bands and viscera, boiled (but not salted), preferably for about 20 2, hour, and then dried, preferably in low-heat mechanical driers such as those employing "heat pump" technology. The dried tissue can further be ground or divided as needed for ultimate use. This process decreases the sodium content of the tissue and helps 25 protect various active ingredients from degradation. This fraction can be formulated and used directly as an anti-inflammatory composition. Another active fraction can be obtained from the flower portion of the sea cucumber. During the 30 evisceration process described above, the anterior portion ("flower") of the sea cucumber is cut away from the viscera and body wall. The isolated flower is then WO 00/01399 PCTIUS99/15168 6 heated, preferably for about ; hour, dried at low temperatures (e.g. between about 140OF and about 180OF using conventional drying apparatus and per se known techniques). This dried fraction, designated "T2000" 5 by the inventor, can then be ground or divided as needed for formulation and use directly as an anti inflammatory composition. Still another anti-inflammatory fraction can be obtained from the epithelial layer of the sea cucumber 10 body wall. Muscle, viscera and flower are removed as described above, followed by isolation of the epithelial layer of the sea cucumber body wall from the harder collagenous layers beneath, preferably by one or more of the following means: 15 - heating the body-wall in water at temperatures from about 140OF to about 180'F, preferably at about 170'F, followed by mechanical separation by hand or machine (e.g., using machines known in the art as mincers or de-boners, which detect tissue 20 density and separate harder tissues from softer tissues); - enzymatic hydrolytic separation, using, e.g., organism's own digestive tract enzymes, proteases from mammalian sources, proteases from non 25 mammalian sources or acidic hydrolazes, preferably Alcalase (NOVO Nordisk Bio Chem, North Carolina), the enzyme preferably being in a solution of about 1% to about 10% enzyme, most preferably in a solution of about 10% enzyme; 30 - scouring/scrubbing or de-boning processes known to those skilled in the potato or chicken processing arts.
WO 00/01399 PCT/US99/15168 7 Heating in water, followed by mechanical separation using a de-boner is most preferred. The epithelial fraction so obtained (designated "B1000" by the inventor) is a dark, moist, viscous, 5 carbohydrate-rich matter. B1000 can be dried as described above, formulated and used directly as an anti-inflammatory composition. Once produced, the B1000 and/or T2000 fractions, other sea cucumber tissues, and kelp, are incorporated 10 into the mixture for the preparation of the "jerky treats" in amounts between 1% and 80% by weight. These therapeutic constituents are then added to the combinations of meat or fish by-products, gelatin, grains, vitamins, minerals, animal fat, preservatives 15 such as BHT and BHA or mixed tocopherols and palatability factors such as beef, meat meal and meat by-products or other flavor-bearing compounds that are mixed and extruded into various shapes, weights, and sizes which can vary widely. 20 In another embodiment of the invention, green tea or green tea extracts are added to the formulation. Green tea is known to contain potent inhibitors of cartilage degradation, for example EGCg, and is a useful adjunct for treating individuals with 25 inflammatory diseases, such as arthritis, that can lead to cartilage degradation. Green tea can be water and alcohol extracted by methods known in the art whereby the phenolic fraction is between 30% and 70%. Green tea extracts having 30%, 50%, 60% and 100% enriched 30 polyphenolics, or specifically green tea catechins, are available commercially and are suitable for use in the present invention. Extracts are incorporated into the WO 00/01399 PCT/US99/15168 8 "jerky stick" of the present invention at percentages of weight between 1% and 80% of the total "jerky stick" delivery form. Alternatively, the pure compound EGCg can be added directly to the "jerky stick" formulation 5 in amounts ranging up to 60% by weight or more, limited by factors such as LD 50 and the physical considerations of maintaining a palatable consistency to the product. Example 1 Preparation of the "Jerky Stick" 10 With Sea Cucumber and Kelp Fractions Jerky sticks were prepared using T2000 from the Sea Cucumber, Cucumaria frondosa, as described above. T2000, together with various palatability factors including, but not limited to, meat, meat by-products 15 and "Norwegian" kelp, Ascophylum nodosum, were added to vitamin E, garlic, lecithin, gelatin, glucosamine (as a hydrochloride salt, although the sulfate salt or any other suitable form) and flax seeds. The T2000 was added at about 8% of the final treat product by weight. 20 The glucosamine constituent was added at 2% of the final treat product by weight. The ingredient mix was then extruded and molded into a jerky stick shape 5 inches long, 1.25 inches wide and approximately 0.25 inches thick, with final weight of 14 grams.
WO 00/01399 PCT/US99/15168 9 Example 2 Preparation of the "Jerky Stick" With Additional Green Tea Fractions The jerky stick was produced as in Example 1, with 5 the addition of a green tea extract containing 30% polyphenolics. The green tea extract, purchased from Indena USA. Seattle WA, USA, Product 36TVD0090-"THE VERT" AQ-ATO-HF, was added to the above recipe at 2% by weight, but can be added at any percentage of the jerky 10 stick weight between 1% and 30% (limited by palatability). This provided an effective dose of 280 milligrams of the green tea extract to the jerky product. It is contemplated that the epigallocatechin 3-gallate (EGCg) is absorbed systemically in mammals, 15 and is effective in inhibiting degradation of cartilage in arthritic joints. In addition, EGCg is thought to provide added synergy to the anti-inflammatory activity of the sea cucumber and the sea cucumber plus glucosamine compounds. 20 Example 3 Effectiveness and Palatability of the "Jerky Stick" in Arthritic Dogs Jerky sticks with added green tea extracts were administered to 4 dogs of unknown breeds at Westside 25 Animal Clinic in Richmond, IN and were found to be palatable. Further, six arthritic dogs in various conditions of lameness were administered jerky sticks as prepared in Example 1. After two weeks of administration at one WO 00/01399 PCT/US99/15168 10 stick per day per 50 pounds of weight, these dogs showed increased mobility as determined by both their owners and veterinarians. In every instance, palatability was not a problem in administration of the 5 jerky. It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons of 10 ordinary skill in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims (4)

1. A dosage form for administering therapeutic agents to animals in need thereof comprising fractions of sea cucumber in percentages of incorporation between 5 1 and 80% by weight, glucosamine HCL or glucosamine sulfate in percentages of incorporation between 1 and 50% by weight and one or more palatability factors in amounts sufficient to successfully render the composition of matter palatable to target animals, said 10 dosage form being of a weight between 1 gram and 30 grams.
2. A method of delivery of sea cucumber fractions to animals by the administration of a formed dosage form which contains an effective amount of sea cucumber 15 fractions.
3. A method to provide increased mobility and relieve nutritional and arthritic or inflammatory symptoms in an animal in need of same by the combining of glucosamine or salts thereof with sea cucumber 20 fractions at percentages of each compound between 1% and 90% to the total.
4. A composition of matter of Claim 1, additionally comprising green tea extract in an effective amount to inhibit inflammation in a mammal in 25 need of same.
AU49694/99A 1998-07-07 1999-07-06 Companion animal therapeutic treat Ceased AU770392B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9441898P 1998-07-07 1998-07-07
US60/094418 1998-07-07
US13769999P 1999-06-07 1999-06-07
US60/137699 1999-06-07
PCT/US1999/015168 WO2000001399A1 (en) 1998-07-07 1999-07-06 Companion animal therapeutic treat

Publications (3)

Publication Number Publication Date
AU770392C AU770392C (en) 2000-01-24
AU4969499A true AU4969499A (en) 2000-01-24
AU770392B2 AU770392B2 (en) 2004-02-19

Family

ID=26788849

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49694/99A Ceased AU770392B2 (en) 1998-07-07 1999-07-06 Companion animal therapeutic treat

Country Status (5)

Country Link
JP (1) JP2002519384A (en)
AU (1) AU770392B2 (en)
CA (1) CA2336602C (en)
GB (1) GB2355196B (en)
WO (1) WO2000001399A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527924A (en) * 1999-01-29 2005-01-28 Mars Uk Ltd Antioxidant compositions and methods for companion animals
GB2367489B (en) * 2000-07-31 2005-02-09 Mars Inc Use of antioxidants
DE60120681T2 (en) * 2000-05-01 2007-05-16 The Iams Company, Dayton METHOD FOR INCREASING IMMUNE RESPONSE IN DOGS USING A GARLIC-CONTAINING DIETETIC COMPOSITION
US6916492B2 (en) 2001-03-30 2005-07-12 Council Of Scientific & Industrial Research Natural nontoxic multicolor fluorescent protein dye from a marine invertebrate, compositions containing the said dye and its uses
US6689391B2 (en) 2001-03-30 2004-02-10 Council Of Scientific & Industrial Research Natural non-polar fluorescent dye from a non-bioluminescent marine invertebrate, compositions containing the said dye and its uses
US6387416B1 (en) * 2001-04-05 2002-05-14 Thomas Newmark Anti-Inflammatory herbal composition and method of use
JP4757413B2 (en) * 2001-09-11 2011-08-24 株式会社高研 Sponge made of sea cucumber or starfish collagen and method for producing the same
FR2831396B1 (en) * 2001-10-31 2004-04-02 Moulin Du Chatel FOOD FOR LAYING HENS FOR THE PRODUCTION OF IODIZED AND POLYUNSATURATED FATTY EDIBLE EGGS AND PROCESS FOR SUPPLYING CORRESPONDING LAYING HENS
JPWO2004091642A1 (en) * 2003-04-11 2006-07-06 協和醗酵工業株式会社 Preventive or therapeutic agent for arthritis
CN102934819B (en) * 2012-10-26 2014-04-02 青岛佳日隆海洋食品有限公司 Trepang capsule and preparation process thereof
GB201414910D0 (en) * 2014-05-23 2014-10-08 Mars Inc Composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044707B (en) * 1968-10-26 1980-04-21 Rotta Research Lab PROCEDURE FOR THE PREPARATION OF GLUCOSANINE SALTS AND PHARMACEUTICAL PREPARATIONS INCLUDING THESE GLUCOSAMINE SALTS AS ACTIVE AGENTS
US4975270A (en) * 1987-04-21 1990-12-04 Nabisco Brands, Inc. Elastomer encased active ingredients
JPH0491027A (en) * 1990-08-02 1992-03-24 Taiho Yakuhin Kogyo Kk Therapeutic agent of human immune deficiency virus
JPH04117329A (en) * 1990-09-05 1992-04-17 Shiseido Co Ltd Composition showing activity related to dissolution of thrombosis
CN1050680A (en) * 1990-10-05 1991-04-17 刘辉明 The manufacture method of Haicibao liquid
CN1045538C (en) * 1993-08-04 1999-10-13 成都市疑难病研究所 Natural composition oral medicine for treating male sterility
US5474033A (en) * 1994-05-05 1995-12-12 Mitchell, Jr.; Robert K. Animal teaching/amusement device
US5464619A (en) * 1994-06-03 1995-11-07 The Procter & Gamble Company Beverage compositions containing green tea solids, electrolytes and carbohydrates to provide improved cellular hydration and drinkability
FR2745978B1 (en) * 1996-03-18 1998-07-17 ORAL TREATMENT PRODUCT FOR ANIMALS
US5770205A (en) * 1996-08-05 1998-06-23 Coastside Bio Resources Tissue fractions of sea cucumber for the treatment of inflammation
US5888514A (en) * 1997-05-23 1999-03-30 Weisman; Bernard Natural composition for treating bone or joint inflammation

Also Published As

Publication number Publication date
GB0100640D0 (en) 2001-02-21
CA2336602A1 (en) 2000-01-13
AU770392C (en) 2000-01-24
GB2355196B (en) 2004-06-09
JP2002519384A (en) 2002-07-02
GB2355196A (en) 2001-04-18
CA2336602C (en) 2010-11-02
AU770392B2 (en) 2004-02-19
WO2000001399A1 (en) 2000-01-13

Similar Documents

Publication Publication Date Title
RU2230458C2 (en) Fodder for domestic animals, method for its preparing and therapeutic method for maintaining healthy joints and deterioration of arthritic symptoms in domestic animals
KR900002027B1 (en) Dietary products and uses comprising methylsulfonylmethane
US20120004157A1 (en) Hydroxyproline compositions and uses thereof
US6428817B1 (en) Companion animal therapeutic treat
US11191814B2 (en) Pet food formulation with cannabinoids
US20070004629A1 (en) K9 and equine joint health food supplement and method of administering
US20080069862A1 (en) Joint preserving nutritional vitamin, mineral and herbal pet supplement
CN1668212A (en) Compositions comprising lactoferrin
AU770392C (en) Companion animal therapeutic treat
BG107626A (en) Application of benzophenanthridine alcaloids as fodder additive and medicamentous form against intestinal inflammation
KR100973192B1 (en) A composition of the functional feed for aged pets
BRPI0410131B1 (en) Dietary supplement for use in the treatment and / or inhibition of digestive tract ulcers in horses and other animals and their method.
CA2822337A1 (en) Pet food compositions and methods for treating arthritis and inflammation associated with arthritis
WO1990009179A1 (en) Treatment of tibial dyschondroplasia
WO2006117184A2 (en) Veterinary composition
JPWO2006120974A1 (en) Health food and pharmaceutical composition for improving diseases of cartilage metabolism disorder
JP2003155250A (en) Healthy hood for relieving arthrodynia
Abd-Allah et al. Influence of using flavomycin and propolis as feed additives on buffalo milk production, and growth performance and blood metabolites of suckling calves
US20100316732A1 (en) Beverage compositions for the promotion of joint health in companion animals
US20070155666A1 (en) Canine and equine collagen joint health supplement
JPH0829051B2 (en) Veterinary formulation
EP1834647A1 (en) Canine and equine collagen joint health supplement
Dharmayudha et al. Soil worms (Lumbricus rubellus) as feed additives for piglets' growth, blood profile and immunomodulators
JP2874633B2 (en) Feed additives
KR100563523B1 (en) Pharmaceuticals to optimize mucus viscosity and stimulate intestinal function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired